Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of September 30, 2013 will be sufficient to fund its currently planned operations into 2015 and through the expected release of final survival results from both the Synergy and Borealis-1 trials. The cash burn is expected to be reduced in 2014 compared with 2013 because the company-sponsored Borealis-1 trial is expected to incur the majority of its costs in 2013.  Further, the investigator-sponsored OGX-427 Phase 2 trials are substantially less capital-intensive than company-sponsored trials. 
  • At November 7, 2013, The Company had 14,707,636 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012Collaboration revenue$
    9,862$
    ,570$
    21,278$
    ,315Operating expenses:  Research and development18,00412,89542,12224,303  General and administrative2,4731,9657,4465,749Total operating expenses20,47714,86049,56830,052Loss from operations(10,615)(8,290)(28,290)(19,737)  Other income5612,3703,1192,742Net loss$
    (10,054)$
    (5,920)$
    (25,171)$
    (16,995)Basic and diluted net loss per share$
    (0.68)$
    (0.40)$
    (1.72)$
    (1.29)Weighted average number of basic and diluted common shares14,690,98414,619,84214,675,24413,141,940Consolidated Balance Sheets(In thousands) September 30,  December 31, 20132012 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    47,091$
    75,697  Interest receivable295327  Amounts receivable9,922714  Prepaid expenses and other current assets2,7133,755  Property, equipment and other assets1,6181,523Total assets$
    ,639$
    82,016Liabilities and stockholder
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
    (Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
    (Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
    (Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
    Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2
    ... Jan. 13 Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE ... into a securities purchase agreement (the "Agreement") with Robert Gipson ... of the Company at a purchase price of $1.00 per ... $1 million. In connection with the Agreement, Mr. Gipson ...
    ... (TSX: GEN), a company focused on developing blood-based ... and personalized health management, today announced it has ... for the detection of Chagas disease related gene ... discovery of a blood biomarker-based method of testing ...
    ... Inc. (OTCBB: JMAR), San Diego, CA, a leading innovator in ... of chemical, biological, radiological, nuclear and explosive (CBRNE) materials, today ... which is the only commercialized, EPA tested, online system for ... ...
    Cached Biology Technology:Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform 2JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 2JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 3JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 4
    (Date:7/10/2014)... 2014  The American Academy of Forensic Sciences ... and Technology (NIST) and the Department of Justice ... forensic science expert members to the Forensic Science ... of the NIST,s Organization of Scientific Area Committees ... appointments made to the new FSSB that has ...
    (Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
    (Date:7/10/2014)... 2014 According to a new ... Control Systems Market Global Forecast, Market Share, Size, Growth ... Access Control systems market was valued at USD 15,406.1 ... a CAGR of 12.6% from 2014 to 2019, to ... 2019. Browse the full Electronic Access Control ...
    Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
    ... in French . , A new brain-imaging ... reveals that ghrelin - a stomach hormone, acts on specific ... related cues and eating for pleasure. This study, published ... to advance understanding and treating obesity, a condition affecting millions ...
    ... for increasing the soil organic carbon (SOC) pool must be ... SOC accrual in NT soils have primarily focused on the ... soil profile. The lack of adequate data on the SOC ... NT farming on SOC sequestration and off-setting CO2 emissions. , ...
    ... Siberian village will discuss their artworks, which are on ... Science (AAAS) Gallery, 1200 New York Ave, NW, Washington, ... old, will describe their works and answer questions from ... 14 May in the AAAS auditorium. The works, mainly ...
    Cached Biology News:Hunger hormone: Makes food more attractive 2Finding the real potential of no-till farming for sequestering carbon 2May 14 AAAS Lecture and videoteleconference on artworks by Siberian schoolchildren 2
    ...
    ...
    Contains L-glutamine....
    ... Agarose-HR High Resolution ... fragments from 50 to ... useful for sizing PCR ... generated by restriction enzyme ...
    Biology Products: